Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people starting Wegovy begin at 0.25 mg — a tolerability dose, not a treatment dose — and stay there for four weeks before any increase. In that first month, the medicine is settling into your system. Significant weight loss at this stage is uncommon, and that is not a sign anything is wrong. Wegovy is a prescription-only medicine; a prescriber assesses your suitability before treatment can begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's mechanism (slowing the rate at which your stomach empties and signalling fullness to the brain via GLP-1 receptors) takes time to reach a steady state. At 0.25 mg, the dose is below the therapeutic threshold by design. Your body is meeting the medicine for the first time.
What people often notice first is not the scales moving but appetite behaving differently. Meals that used to feel automatic become noticeably smaller before you feel full. Some people describe a quieting of the background hunger that usually runs all day. For a detailed breakdown of what tends to shift in the opening days, the first week on Wegovy page covers that window specifically.
The NHS notes that semaglutide's most common early effects are gastrointestinal (nausea in particular) and that these usually settle over time. Worth knowing: if you track your weight, weigh yourself at the same time of day, after the same routine, and once a week rather than daily. Day-to-day fluctuations from water, food and digestion tell you almost nothing useful at this stage.
The side-effect profile in the first four weeks is dominated by the gut. Nausea is the most frequently reported, followed by changes in bowel habits (looser stools for some, constipation for others) along with burping, indigestion and occasional fatigue. Most people find these effects are worst in the two or three days after each injection, then fade before the next dose is due.
Headaches and mild dizziness are also reported, particularly if calorie intake drops sharply. Keeping meals regular, staying well hydrated and eating slowly all make a practical difference. Fatty or very rich food tends to amplify nausea, so lighter meals in the early weeks are worth trying.
The full Wegovy overview on this site covers the complete side-effect picture and what the prescribing information says about managing them. If you experience severe, persistent stomach pain (particularly if it radiates toward the back) seek medical advice promptly; pancreatitis, though uncommon, is a recognised risk with this class of medicine, and the MHRA has highlighted it in their Drug Safety Update guidance. Any suspected side effects can be reported at yellowcard.mhra.gov.uk.
In the STEP 1 trial (68 weeks, adults with obesity, semaglutide 2.4 mg versus placebo) the average total weight reduction was around 15%. That figure built gradually over the full trial period. Early data from the same research shows the first month typically accounts for only a fraction of total eventual loss, particularly while participants were still on the starter dose.
Individual variation at this stage is wide. Some people see two or three kilograms shift in the first month; others see less. Factors including starting weight, diet, activity levels and how strongly the body responds to the starter dose all play a role. If you are wondering whether you lose weight in the first month of Wegovy, that page sets out what people typically experience during that opening period, and how the figures tend to vary.
The more instructive question, clinically, is what happens from months two and three onward, once the dose has been titrated upward and the medicine is working at a therapeutic level. For a closer look at what people report seeing on the scales and in their appetite by the four-week mark, the Wegovy first month results page brings together what the evidence and real-world accounts suggest. For the fuller picture of what the evidence shows over a longer arc, how long Wegovy takes to work sets out the timeline in detail.
Wegovy is injected once weekly, subcutaneously (typically the abdomen, thigh or upper arm) and the pen needs to be stored in the fridge between uses. It is worth knowing your injection day before you begin and making it consistent each week, since the medicine works on a seven-day rhythm. The patient information leaflet that comes with your pen is the authority on storage windows, injection technique and what to do if a dose is missed; read it before your first injection, not after.
If you are on oral contraceptives, the NHS England guidance on weight-management injections notes that absorption of the pill may be affected; discuss additional contraceptive cover with your prescriber. Cost is also worth thinking through before you commit, the Wegovy price page sets out what private treatment typically involves in the UK. If you would like to explore whether Wegovy is clinically suitable for you, our prescribers at the consultation page can review your details the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.